Hanna Fröhlich, Felix Henning, Tobias Täger, Dieter Schellberg, Morten Grundtvig, Kevin Goode, Anna Corletto, Syed Kazmi, Torstein Hole, Hugo A Katus, Dan Atar, John G F Cleland, Stefan Agewall, Lutz Frankenstein, Andrew L Clark
AIMS: Angiotensin-converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. METHODS AND RESULTS: A total of 4723 outpatients with stable HFrEF prescribed enalapril, lisinopril, or ramipril were identified from three registries in Norway, England, and Germany. In three separate matching procedures, patients were individually matched with respect to both dose equivalents and their respective propensity scores for ACEI treatment...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy